NCT05326750 Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
| NCT ID | NCT05326750 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kuopio University Hospital |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-11-21 |
| Primary Completion | 2032-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2022-11-21 with a primary completion date of 2032-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.
Eligibility Criteria
Inclusion Criteria: * Mild Cognitive Impairment due to Alzheimer's disease * Dementia with Lewy Bodies * Frontotemporal dementia * Idiopathic normal pressure hydrocephalus (iNPH) Exclusion Criteria: * History of seizures * Pregnancy * Metal implants in the head (except dental fillings) * Electronic implants (i.e. pace-maker, implanted medical pump) * Age \<18 years
Contact & Investigator
Eino Solje, MD, PhD
PRINCIPAL INVESTIGATOR
Kuopio University Hospital
Frequently Asked Questions
Who can join the NCT05326750 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05326750 currently recruiting?
Yes, NCT05326750 is actively recruiting participants. Contact the research team at eino.solje@uef.fi for enrollment information.
Where is the NCT05326750 trial being conducted?
This trial is being conducted at Kuopio, Finland.
Who is sponsoring the NCT05326750 clinical trial?
NCT05326750 is sponsored by Kuopio University Hospital. The principal investigator is Eino Solje, MD, PhD at Kuopio University Hospital. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.